Cohere buys biopharma analytics firm Reliant AI
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Cohere Inc. is edging into the life sciences sector with the acquisition of a data analytics platform servicing the biopharma industry.
The Canadian artificial intelligence company announced the purchase Tuesday but would not say how much it is paying for Reliant AI nor how the deal is structured.
The transaction marries Cohere, a seven-year-old firm making AI tools for businesses including RBC, Bell and Oracle, with a more nascent company cornering the lucrative and crucial biopharmaceutical industry.
Reliant AI’s technology makes it easier for life sciences teams to collect, organize and analyze complex data. Products from the firm founded in 2023 are being used by GSK PLC, Kyowa Kirin and OMass Therapeutics.
Cohere chief executive Aidan Gomez positioned the purchase as a way to deepen his company’s work across health care and biopharma.
Health care alone “represents one of the most consequential opportunities for AI” and “demands secure, sovereign, and domain-specific systems,” he said in a statement.
“Together, we will accelerate progress in health care, building on our shared footprint across Canada and Germany to serve these critical sectors.”
As part of the acquisition, Reliant’s staff of about 30 will make the leap to its new parent company, said Cohere spokesperson Patrick Allen.
Reliant AI co-founder and CEO Karl Moritz Hermann will become Cohere’s vice-president of AI verticalizations. Reliant co‑founder Marc Bellemare, based in Montreal, will become Cohere’s vice-president of modelling.
Moritz Hermann saw the sale of his company, which has offices in Montreal, Berlin and Denver, as a way to securely scale the work Reliant has done.
“Our combined expertise will accelerate drug discovery and research innovation for customers around the world,” his statement said.
Cohere’s purchase comes as it is in the process of merging with German AI firm Aleph Alpha. The firm they will form will use the Cohere name and be “anchored in” Germany and Canada, if Aleph Alpha shareholders approve the deal.
This report by The Canadian Press was first published May 19, 2026.
